LC
AKRO

Lindbrook Capital’s Akero Therapeutics AKRO Stock Holding History

Lindbrook Capital’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$65.1K Buy
1,609
+50
+3% +$2.12K 0.01% 879
2024
Q4 		$43.4K Hold
1,559
– – ﹤0.01% 880
2024
Q3 		$44.7K Buy
1,559
+20
+1% +$521 ﹤0.01% 874
2024
Q2 		$36.1K Buy
1,539
+19
+1% +$406 ﹤0.01% 932
2024
Q1 		$38.4K Hold
1,520
– – ﹤0.01% 893
2023
Q4 		$35.5K Buy
1,520
+51
+3% +$1.01K ﹤0.01% 893
2023
Q3 		$74.3K Buy
1,469
+15
+1% +$698 0.01% 553
2023
Q2 		$67.9K Hold
1,454
– – 0.01% 611
2023
Q1 		$55.6K Sell
1,454
-56
-4% -$2.5K 0.01% 660
2022
Q4 		$82.7K Buy
1,510
+31
+2% +$1.33K 0.01% 539
2022
Q3 		$50K Buy
1,479
+1,347
+1,020% +$20.6K 0.01% 639
2022
Q2 		$1K Buy
+132
New +$1.38K ﹤0.01% 2131

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Lindbrook Capital's AKRO Position: Q1 2025 in Review

Lindbrook Capital increased its Akero Therapeutics (AKRO) stake by 3.2% in Q1 2025, buying an estimated $2.12K and bringing the position to 1,609 shares worth $65.1K. The position accounts for 0.01% of the portfolio, ranked #879.

Lindbrook Capital first reported a position in AKRO in Q2 2022 and has held it in 12 quarters since. The position peaked at $82.7K in Q4 2022. 240 funds tracked by Wall St. Rank hold AKRO as of Q1 2025.

  • Lindbrook Capital held 1,609 shares of Akero Therapeutics worth $65.1K as of Q1 2025.
  • Lindbrook Capital bought 50 Akero Therapeutics shares in Q1 2025, an estimated $2.12K.
  • Akero Therapeutics made up 0.01% of Lindbrook Capital's portfolio in Q1 2025, its #879 holding.
  • Lindbrook Capital first reported a position in Akero Therapeutics in Q2 2022 and has held it in 12 quarters since.
  • Lindbrook Capital's Akero Therapeutics position peaked at $82.7K in Q4 2022.
  • 240 funds tracked by Wall St. Rank held Akero Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.